Thymulin vs VIP
A side-by-side research comparison of Thymulin and VIP across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Thymulin | VIP |
|---|---|---|
| Full name | Thymulin (Facteur Thymique Serique) | Vasoactive Intestinal Peptide |
| Category | Immune Support | Immune Support |
| Status | Research compound | Research compound |
| Mechanism | Binds to specific receptors on T-cell precursors promoting their differentiation into mature T-cells, modulates cytokine production, and requires zinc as cofactor. | Activates VPAC1 and VPAC2 receptors, raising intracellular cAMP. This dampens pro-inflammatory cytokine production, supports vasodilation and pulmonary function, and modulates regulatory T-cell activity. |
| Molecular weight | 847.9 Da | ~3326 Da |
| Half-life | ~2 hours | Very short (~1-2 minutes in plasma) |
| Bioavailability | ~80% subcutaneous | Intranasal (most common in protocols); rapidly degraded systemically |
| Typical dose | 1-5 mg | ~50 mcg per spray |
| Frequency | 2-3x per week | 1-4x daily |
| Route | Subcutaneous injection | Intranasal spray |
Thymulin reported benefits
- T-cell maturation support
- Thymic function restoration
- Zinc-dependent immune activation
- Anti-inflammatory properties
VIP reported benefits
- Broad anti-inflammatory effect
- Supports pulmonary and vascular function
- Immune modulation (regulatory T cells)
- Used in chronic inflammatory response protocols
Related comparisons
Research and educational reference only. Not medical advice.